Plandaí Biotechnology, Inc. Announces Favorable Anti-Malaria Test Results In Second Round Of In Vitro Testing

Plandaí Biotechnology, Inc. Announces Favorable Anti-Malaria Test Results In Second Round Of In Vitro Testing

Jun 20, 2013 (ACCESSWIRE via COMTEX) -- Results indicate 12 times greater efficiency in killing parasite

SEATTLE, WA--June 20, 2013--Plandaí Biotechnology, Inc. (otcqb:PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced the results of further in vitro testing of the Company's Phytofare™ Catechin Extract in killing the malaria parasite, plasmodium falciparum. The investigations, independently undertaken by Cape Town Bioanalytical Services, South Africa, used the complete Phytofare™ complex rather than just the isolated EGCG catechin used in earlier studies, and the results confirmed a twelve times greater efficiency over prior results.

Roger Duffield, Chief Executive Officer of Plandaí, commented, "Green tea catechins, while scientifically proven to have tremendous wellness benefits, are often not reproducible in human subjects. These antioxidants suffer from significant drawbacks through having poor bioavailability, meaning the nutrients are poorly absorbed in human tissues and have difficulty crossing human membranes as well as being rapidly and thoroughly metabolized in the digestive tract. This results in only a small amount of the antioxidants actually reaching the bloodstream in an unaltered state.

"The investigations by Cape Town Bioanalytical Services, South Africa now corroborate the 2012 published USDA investigations with carotenoids validating increased efficacy levels of live plant antioxidants when produced through the proprietary CRS system.

"To complete the commercial delivery system, scientists in South Africa will undertake a program of encapsulating Phytofare™ catechin complex into a proprietary nanodelivery system that should deliver improved bioavailability and protection against gut metabolism, allowing our super antioxidants to remain protected and intact until they reach the bloodstream. We believe that this combination will finally allow medical science to unlock the promised health benefits of many botanical drugs."

These further independent scientific investigations of Phytofare™ Catechin Complex in both powder and nano-encapsulated forms will be undertaken both in vivo and mouse models to validate the extract for oral and topical formulations as an antimalarial drug target and in human skin maintenance including antiaging.

The antiaging in vitro studies are expected to be released by the end of August 2013, leading to mouse models and in due course human trials.

About Plandaí Biotechnology, Inc.

Plandaí Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts, which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandaí Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing the patented Phytofare™ extracts in-house allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include food and beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit

Safe Harbor Statement

The information provided may contain forward-looking statements and involve risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Plandaí's ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Plandaí is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.


Andrew Beyer

Phone: 619-202-7456

Email: [email protected]í

Source: Plandaí Biotechnology, Inc.